Monogram Orthopaedics Inc(MGRM) 2023 Earnings Summary
Bullish Points:
1. Monogram Orthopaedics is in the early stage of development and primarily focuses on developing patient-optimized orthopedic implants using 3D printing and robotics.
2. The company raised $21,129,000 from the sale of 3,154,786 shares of Series B Preferred Stock in the Series B Offering, which was terminated on February 18, 2022.
3. Monogram commenced a Regulation Crowdfunding offering (Series C Offering) on July 14, 2022, seeking up to $5,000,000 from the sale of Series C Preferred Stock. As of the report date, the company has sold approximately 72,228 shares of Series C Preferred Stock for gross proceeds of $723,002.
4. The primary addressable market for Monogram Orthopaedics is knee procedures, specifically primary Total Knee Arthroplasty (T.K.A.) procedures.
5. Monogram Orthopaedics Inc. is focusing on cementless knee fixation and expects procedure volumes to increase due to demographic tailwinds and rising adoption of uncemented implant use.
6. The global market for Knee Joint Reconstruction Sales in 2020 was estimated to be $7.8 billion, down from $9.3 billion in 2019, and is projected to increase to $10.2 billion by 2023.
7. Monogram is actively commercializing a robotic surgical system and press-fit primary knee implants.
Bearish Points:
1. For the six months ended June 30, 2022, the company did not generate any revenues, compared to $628,000 in revenues from sales of licensed third-party products during the same period in 2021.
2. Operating expenses increased by 10.4% to $5,600,668 for the six months ended June 30, 2022, compared to $5,071,553 for the same period in 2021.
3. Net loss for the six months ended June 30, 2022, was $6,364,096, compared to a net loss of $5,151,838 for the same period in 2021.
4. The company had an accumulated deficit of $30.4 million at June 30, 2022, and generated negative cash flows from operations of $5.1 million for the six months ended June 30, 2022.
5. The company is facing substantial doubt about its ability to continue as a going concern due to financing requirements and future operations.
The final result you summarize based on positive and negative content needs to be objective, neutral, and dialectical. For more information, you can read the original text of Monogram Orthopaedics Inc(MGRM)'s financial report: https://www.sec.gov/Archives/edgar/data/1769759/000110465922103314/tm2226693d1_1sa.htm
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
